NextCure Delays 2 Clinical Trials Due to Coronavirus

NextCure Delays 2 Clinical Trials Due to Coronavirus

Source: 
Motley Fool
snippet: 

On Monday, clinical-stage biopharmaceutical company NextCure (NASDAQ: NXTC) announced that it would be delaying the start of upcoming phases of clinical trials for two immuno-oncology drug candidates, NC318 and NC410.